Table 4.

Clinical and oncological outcomes of included trials

Clinical/oncological outcomes	No. of studies	SEA		CJP		Effect estimate		Heterogeneity
		Events	Total	Events	Total	RR/WMD (95% CI)	P	I2	P
Anastomotic leakage	7 [31–36, 39, 40]	20	279	33	281	0.68 (0.41, 1.13)	0.14	0%	0.42
Anastomotic stricture	3 [32, 34, 41]	4	165	4	158	0.97 (0.29, 3.25)	0.96	0%	0.19
Pouch-related complications	4 [31, 34, 36, 41]	1	188	4	187	0.50 (0.13, 1.96)	0.32	0%	0.63
Pelvic sepsis	4 [31, 32, 36, 38]	17	151	10	158	1.77 (0.87, 3.59)	0.11	0%	0.84
Intestinal obstruction	4 [32, 36, 38, 41]	13	208	13	209	1.08 (0.53, 2.24)	0.83	0%	0.43
Wound infection	4 [32, 36, 38, 41]	6	208	5	209	1.18 (0.39, 3.62)	0.77	0%	0.84
Rectovaginal fistula	3 [31, 34, 41]	3	145	3	137	0.95 (0.24, 3.79)	0.94	0%	0.42
Urinary complications	3 [32, 34, 36]	8	121	12	128	0.72 (0.31, 1.69)	0.45	0%	0.53
Cardiovascular complications	2 [32, 36]	3	93	2	100	1.55 (0.31, 7.76)	0.59	0%	0.62
Pneumonia	2 [32, 36]	2	93	3	100	0.79 (0.16, 3.85)	0.77	0%	0.51
Mortality (in-hospital/< 30days)	3 [32, 36, 41]	5	189	3	185	1.53 (0.43, 5.45)	0.51	39%	0.20
Reoperations (except stoma reversal)	3 [32, 36, 38]	17	130	25	134	0.74 (0.36, 1.52)	0.41	24.7%	0.27
Relapse (< 2 year)	2 [36, 38]	4	80	4	84	1.05 (0.27, 4.03)	0.947	0%	0.99
Postoperative hospital stay (day)	4 [32, 36, 38, 39]	-	160	-	156	0.42 (− 1.72, 2.56)	0.70	30.5%	0.23